Despite global declines in liver cancer mortality attributed to hepatitis B and C, liver cancer mortality rose sharply in the Americas, driven by an increase in nonalcoholic steatohepatitis, according ...

A therapeutic being tested for nonalcoholic steatohepatitis (NASH) and liver fibrosis showed statistically significant improvement versus placebo on two primary endpoints in a one-year, Phase 2b trial ...

The FDA has qualified the first AI-based drug development tool to support metabolic dysfunction-associated steatohepatitis clinical trials. The cloud-based tool, AI-Based Histologic Measurement of ...

When left uncontrolled, fatty liver disease can progress to severe conditions, including non-alcoholic steatohepatitis (NASH) ...

The unmet need in non-alcoholic steatohepatitis (NASH) is getting bigger and bigger. In the decade up to 2032, the number of diagnosed cases in seven major markets is forecast to grow by 4.5 million, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Loomba: BIO89-100 is being developed and investigated ...

Nonalcoholic steatohepatitis (NASH) is a serious progressive liver disease caused by excessive fat accumulation in the liver that induces chronic inflammation, resulting in progressive fibrosis ...

Liver disease researchers, stumped by a complex disease, are looking for new investigative tools. Artificial intelligence might be one of them. At a small conference of the American Association for ...

WASHINGTON — In patients with cirrhosis associated with non-alcoholic steatohepatitis (NASH), 1 year of treatment with the investigational oral thyromimetic agent resmetirom (MGL-3196) was safe and ...

NASH, has received FDA approval to revolutionize liver disease drug trials. This innovative technology assists pathologi ...

According to preliminary results released Tuesday, the Akero drug efruxifermin led to at least one stage of improvement in a measure of fibrosis, or liver scarring, that develops from the fatty liver ...